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D26, the T cell activation molecule, is a 110-kD gly-
coprotein that is also present on epithelial cells of
various tissues, including the liver, kidney, and intestine.
CD26 possesses a known dipeptidyl peptidase (DPP)IV ac-
tivity in its extracellular domain (1). A paper by Wesley et
al. in this issue indicates a possible role for CD26/DPPIV
in suppressing malignant transformation of melanocytes to
melanoma (2). The series of work by Houghton and col-
leagues, focusing on melanoma and melanocytes, has
shown that loss of expression and its enzymatic activity of
CD26/DPPIV occurs during malignant transformation of
melanocytes into melanoma (3). The exact pathological
role of its disappearance however, has been unclear. Wes-
ley et al. now elegantly demonstrate that the inducible gene
transduction of CD26 into melanoma cells reverses the ma-
lignant phenotype of the cells toward “benign” melano-
 
cyte-like phenotype, characterized by loss of tumorigenicity,
reappearance of anchorage-dependent growth, restoration
of a block in differentiation, and serum dependence. They
further show that mutant DPPIV lacking serine protease
activity is also able to restore the serum dependence in mel-
anoma cells. Finally, the recruitment of another serine pro-
 
tease, fibroblast activation protein-
 
a
 
, may partly account
for this reversal by mutant DPPIV.
What is the mechanism of such biological behavior of
CD26/DPPIV in melanocytes and melanoma? The authors
suggest the possibility that CD26/DPPIV might degrade
autocrine growth factors, which are yet unidentified and
hence regulate (suppress) the growth of benign melano-
cytes. These findings are quite impressive, as they present
direct evidence that the loss of surface expression of CD26/
DPPIV plays a pivotal role in malignant transformation of
melanocytes toward melanoma.
Besides CD26/DPPIV, this serine protease family also
consists of a group of membrane-associated enzymes (ec-
topeptidases) including CD10/NEP, CD13/APN, and BP-
1/6C3/APA, which are zinc metallopeptidases (4). The ex-
pression of these ectopeptidases, including CD26/DPPIV,
and their roles in various malignancies are under intense in-
vestigation.
Analogous to the loss of CD26/DPPIV in melanoma,
 
the cell surface expression of CD10/NEP is lost during
the development of androgen-independent prostate cancer
from its androgen-dependent phenotype (5). Indeed, Shipp
et al. (6) demonstrated that CD10/NEP inhibits the growth
of small cell carcinoma (SCC) of the lung through the
cleavage of bombesin-like peptides, which are autocrine
growth factors for those cells. They further showed that ex-
pression levels of CD10/NEP in the SCC cells were re-
duced and that the growth of SCC was inhibited by
CD10/NEP and potentiated by CD10/NEP inhibition.
In marked contrast to the inverse correlation between
the expression of CD26 and malignant transformation of
melanocytes, a direct correlation between disease aggres-
siveness and the expression of CD26 in T cell lymphomas
has been reported by Carbone et al. (7). They also showed
that the expression of CD26 and CD40L was mutually ex-
clusive, with CD40L being expressed on slowly progressing
diseases (7). In accordance with these findings, upregula-
tion of CD26/DPPIV on the surfaces of tumor cells has
been recently reported in cases of T cell acute lymphoblas-
tic leukemia. The presence of CD13/APN on neoplastic
lymphocytes showed a significant association with such un-
favorable clinicoprognostic factors in B cell chronic lym-
phocytic leukemia as advanced clinical stage and the diffuse
pattern of bone marrow infiltration. Besides hematologic
malignancies, the upregulation of ectopeptidases has been
reported in a variety of solid tumors. For example, it has
been well established that follicular cell–derived thyroid
carcinomas (papillary carcinoma, Hürthle cell carcinoma,
and follicular carcinoma) express high levels of CD26/
DPPIV, whereas thyroid glands with benign conditions are
exclusively negative for CD26 expression. Therefore, the
analysis of CD26/DPPIV expression and/or its enzymatic
activity may be a powerful tool for the purpose of cytologic
diagnosis of the specific types of thyroid carcinoma (8). In
addition, DPPIV activity is higher in cases of basal cell car-
cinoma than in normal skin or benign lesions. Along with
CD26/DPPIV, CD13/APN has been reported to be up-
regulated in breast carcinomas (9). Thus, the upregulation 
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or downregulation of these ectopeptidases appears to be tis-
sue specific, and even cell type specific, in a variety of ma-
lignancies.
How to explain the distinct roles of CD26 in malignan-
cies? How is this tissue and cell type specificity derived?
First, it may be partly due to the multifunctional nature of
CD26/DPPIV. CD26/DPPIV has several functions besides
its DPPIV enzymatic activity, such as its association with
adenosine deaminase (ADA) and CD45, its costimulatory
effects on T cells, and its function as a receptor for extracel-
lular matrix proteins such as fibronectin and collagens (10).
On human T cells, CD26 expression appears late in thy-
mic differentiation and is preferentially restricted to the
CD4
 
1
 
 helper/memory population. Remarkably, CD26 can
deliver a potent co-stimulatory T cell activation signal to
the CD3 and CD2 pathways or after PMA treatment in the
absence of either exogenous IL-2 or accessory cells (1). The
isolated cDNA for CD26/DPPIV predicted a type II mem-
brane protein of 766 amino acids with G-W-S-Y-G at po-
sitions 628–632 in its putative extracellular domain, which
fits the consensus sequence (G-X-S-X-G) of the catalytic
site of the serine protease family (11). Studies performed
with enzyme inhibitors have implicated DPPIV enzymatic
activity in antigen-induced and/or mitogen-induced T cell
proliferation and lymphokine production (12). These stud-
ies principally suggested that DPPIV activity is necessary
for certain T cell activation pathways.
The human CD26 cDNA was mutated to encode a pro-
tein in which the putative catalytic serine residue at posi-
tion 630 is replaced by alanine (1). We examined the comi-
togenic effect of stimulation through CD3 and CD26 Ag
on IL-2 production using Jurkat T cells expressing wild-
type CD26 (DPPIV
 
1
 
) or mutant CD26 (DPPIV
 
2
 
). Sur-
prisingly, the DPPIV
 
1
 
 Jurkat cells produced substantially
more IL-2 than the DPPIV
 
2
 
 cells on the coengagement of
CD3, suggesting that the DPPIV enzymatic activity of
CD26 by itself may contribute to IL-2 production in the
costimulation of CD3 and CD26. These results directly
support the notion that CD26 plays an important role in T
cell costimulation
Because CD26 has only six amino acids in its cytoplas-
mic region, other signal-transducing molecules may be as-
sociated with CD26, which may account for the costimula-
tory activity of CD26. We have shown that CD26 was
comodulated on the T cell surface with CD45RO, a
known membrane-linked protein tyrosine phosphatase,
and was associated with CD45 in T cells (1). Moreover, it
was demonstrated that modulation of CD26 from T cell
surface induced by anti-CD26 led to enhanced phosphory-
lation of CD3
 
z
 
 tyrosine residues and increased CD4-associ-
ated p56
 
lck
 
 tyrosine kinase activity (1). Thus, one possible
mechanism for this costimulatory activity involves the asso-
ciation of CD26 with the membrane-linked protein ty-
rosine phosphatase CD45.
Another candidate for the signal transduction molecule is
a 43-kD protein associated with CD26 in PHA-activated
blast cells and CD26-transfected Jurkat cells (1) that was
identified as the human ADA (13). ADA is present on the
cell surface as well as in the cytoplasm of human fibroblasts,
renal rabbit tubular cells, and human mononuclear blood
cells (1) (highest expression in lymphocytes), and it cata-
lyzes the conversion of adenosine and deoxyadenosine to
inosine and deoxyinosine, respectively. Despite its wide
distribution, ADA deficiency causes SCID in humans (14).
The inhibition of ADA activity by deoxycoformycin re-
sults in reduction of TCR/CD3-mediated inositol phos-
pholipid hydrolysis and calcium flux (15), implying possible
involvement of ADA in early events of T cell activation. It
was found that ADA coexpressed with CD26 on the cell
surface can block the inhibitory effect of adenosine using
CD26-transfected Jurkat cells. The CD26-transfected Jur-
kat cells that coexpressed ADA and CD26 on the cell surface
were shown to be resistant to the inhibitory effect of ADA
on cell proliferation and IL-2 production, showing a marked
contrast with the case of the control cells without ADA
and CD26 detected on their surfaces. These data strongly
suggest that ADA expressed on the T cell surface can aid
the cell in resisting an inhibitory effect of adenosine by re-
ducing the effective extracellular concentration of adenosine.
This complex formation of CD26–ADA–adenosine may
also be involved in the pathogenesis of some diseases. In-
deed, hairy cell leukemia and chronic lymphocytic leuke-
mia are lymphoid malignancies, which can express high
levels of ADA and CD26. Perhaps their dramatic response
to 2-deoxycoformycin and 2-chlorodeoxyadenosine, known
inhibitors of ADA (16), relates to their surface expression of
the ADA–CD26 complex.
ADA and CD26 expressed on T cells may play an im-
portant role in the catalytic removal of local adenosine,
which in turn could exaggerate the inflammatory response
or provide the growth advantage of lymphoid malignancies
(1). Thus, the costimulatory nature and recruitment of
ADA by CD26 may confer a proliferative advantage to
tumor T cells that in turn allows cancer cells to escape from
immunosurveillance through the downregulation of CD26/
DPPIV on their cell surfaces. This reciprocal effect on both
lymphoid lineage and epidermoid lineage may contribute
to the tissue- and cell type–specific results. It should be
noted that development of malignant tumors in vivo is reg-
ulated not only by their own cell growth but also by a vari-
ety of surrounding cells. Of particular interest is the report
by Gruss et al. showing that T cells in the vicinity of
Hodgkin’s and Reed-Sternberg cells do not express the
CD26 antigen, and that these CD26
 
2
 
 T cells remain
CD26
 
2
 
 even after stimulation in vitro, indicating an inef-
fective activation of T cells in Hodgkin’s disease–involved
tumor lesions (17).
Another possibility, as proposed by Wesley et al. (2), is
that chemokines might act as growth factors for malignant
cells, which may be the substrate for CD26/DPPIV or
other ectopeptidases. In fact, the existence of a transformed
cancer cell line that produces and excretes CC chemokines
into the culture supernatant has been reported previously
(18), although it is not clear whether those chemokines act
as autocrine growth factors.
Reported physiological substrates for CD26/DPPIV in- 
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clude substance P, 
 
b
 
-casomorphin, kentsin, somatoliberin,
growth hormone releasing factor, the neuropeptides, and
the fibrin 
 
a
 
 chain. CD26/DPPIV and/or CD13/APN
were unable to cleave rIL-1
 
a
 
, IL-2, rG-CSF, or natural IL-2
despite the presence of susceptible NH
 
2
 
-terminal se-
quences. Therefore, physiological substrates related to the
immunological aspects of CD26/DPPIV have not yet been
identified.
Recently, Oravecz et al. (19) have demonstrated CD26-
mediated cleavage of RANTES (regulated on activation,
normal T cell expressed and secreted) on Ca
 
2
 
1
 
 mobilization
in T cells and monocytes. In accordance with their results,
we have, and the differential effect of full length (AA 1-68)
and truncated (AA 3-68) RANTES also found that
RANTES was digested by soluble CD26 at the exact posi-
tion of its specificity. Furthermore, we have demonstrated
that soluble rCD26 enhances transendothelial migration of
T cells induced by RANTES, whereas it reduces the mi-
gratory response of monocytes (20). This differential regu-
lation of the transendothelial migration of T cells and
monocytes seems to be partly explained by CD26-medi-
ated cleavage of RANTES; however, synthetic RANTES
(amino acid 3–68) lacking two NH
 
2
 
-terminal amino acids
showed equivalent chemotactic activity to its full length
form on resting T cells, suggesting that other mechanisms
may be involved in the enhancement of T cell migration
by CD26. These findings have led us to propose that
CD26/DPPIV may be involved in the switching of the in-
nate and acquired immune responses. The receptors for
RANTES are CCR1, CCR3, CCR4, and CCR5 (21).
According to the reports by Oravecz et al. (19) and Struyf
et al. (21a),  the soluble CD26/DPPIV-mediated loss of
chemotactic activity of RANTES in monocytes may be
due to its loss of signal transducing ability through CCR1
and/or CCR3. Furthermore, a growing body of evidence
has shown that other CC chemokines, such as eotaxin,
macrophage-derived chemokine, and stromal cell–derived
factor 1 (22) are also cleaved and/or subsequently modu-
lated in their receptor specificities. Another ectopeptidase,
CD13/APN was also found to degrade IL-8 and inactivate
its chemotactic activity. This cleavage and inactivation of
IL-8 was significantly inhibited by the presence of bestatin
or anti-CD13 mAb, indicating that CXC chemokines as
well as CC chemokines are also processed and modulated
by one of the ectopeptidases (23).
The modulation of the NH
 
2
 
 termini of chemokines is of
great importance not only for binding to their receptors
and the following reactions but also for altering the recep-
tor specificity of the processed chemokine and producing
endogenous inhibitor of intact chemokines. While interfer-
ing with the putative autocrine loop as suggested by Wes-
ley et al. (2), cleavage of chemokines may have profound
effects on the responder cells. Judging from the enormous
complexity and redundancy of the various chemokines and
their receptors, one could not easily predict the biological
outcome of cleavage of specific chemokines by the ec-
topeptidases. Additionally, there may be interplays among
different ectopeptidases, as there may be colocalization of
Figure 1. Schematic view: complexity of the site of action and clinical significance of CD26/DPPIV. CD26/DPPIV is a multifunctional ectoenzyme
that may elicit biological effects on various aspects of development and progression of malignancy. The scheme summarizes some of these effects, includ-
ing modulation of growth factors and adenosine, alteration of immunosurveillance, promotion of cellular invasion, and metastasis. 
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CD13, CD10, and CD26 in various cell types, with their
expression differentially regulated by various stimuli (4).
There may be cooperation among these ectopeptidases in
processing the substrates and, thus, tissue specificity may
depend on the interplays among these enzymes.
Another explanation may be that malignant transforma-
tion or tumor development is the end result of a complex
set of processes with multiple steps. Particularly, the devel-
opment of metastasis and invasive ability of malignancies
should be taken into account, as well as tumor growth,
which might cause variation in the biological and clinical
effects of these ectopeptidases. In this context, the binding
ability of CD26/DPPIV with fibronectin (FN) and col-
lagen may confer an aggressive or metastatic phenotype to
tumor cells. Indeed, we reported that peripheral T cells mi-
grating through a monolayer of endothelial cells on col-
lagen gels expressed the highest CD26, whereas CD26 of
adherent (nonmigrating) cells was divided into negative
and high expression (24). Along this line, Cheng et al. (25)
have demonstrated the existence of DPPIV and FN-medi-
ated adhesion and metastasis in lung endothelial cells and
breast cancer cells, in which case DPPIV is expressed on
the endothelial cells and FN is expressed on the cell sur-
faces of the malignant cells. Furthermore, the peptidase ac-
tivity of the ectoenzymes has been implicated in the pro-
cess of invasion and metastasis through the degradation of
the extracellular matrix, as has been suggested in the case
of the metalloprotease superfamily (26). The possible role
of ectopeptidases in these processes has been supported by a
pharmacological study showing the inhibition of tumor
cell invasion and matrix degradation by aminopeptidase in-
hibitors. Furthermore, there may be considerable impor-
tance in the series of work by Chen et al. (27), suggesting
the existence of CD26/DPPIV and fibroblast activation
protein-
 
a
 
, another cell surface serine protease, at the “inva-
dopodia,” or the site of invasion of tumor cells. Interest-
ingly, in their recent review on CD13/APN (28), Rie-
mann et al. propose that focal adhesion kinase (FAK) might
be a point of convergence between adhesion and peptidase
substrates, as FAK is activated and auto-phosphorylated by
ligation of integrins as well as peptidase substrates such as
selected neuropeptides and chemokines (29). FAK may
transduce growth-promoting and/or antiapoptotic signals
through complex formation with various kinases such as
Src, phosphatidylinositol 3 kinase, and adaptor proteins
such as Grb-2, p130/Cas, and pp105/Cas-L (30). It is par-
ticularly interesting that peptidase-mediated regulation of
FAK may have some effects on cell adhesion and motility
as well as contact inhibition or anchorage-dependent
growth of normal and malignant cells. Fig. 1 schematically
summarizes the complex functions of CD26/PPIV.
As discussed above, CD26/DPPIV demonstrates a pleth-
ora of biological functions in a variety of tissue types, both
benign and malignant. These diverse functions may also be
responsible in part for the different roles of CD26 in vari-
ous clinical settings. At this time, it is not possible to fully
discern the molecular mechanisms that explain its various
functional effects. However, as can be seen in the elegant
work by Houghton and colleagues, the precise role of this
intriguing molecule in malignant transformation is begin-
ning to be elucidated, at least at the cellular level. Future
work specifically targeting the expression of CD26 and its
DPPIV enzymatic activity will undoubtedly contribute to a
further understanding of its role in various physiological
states in a variety of tissue contexts, hopefully leading to
therapeutic approaches that are based on our precise under-
standing of CD26 biology.
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